Progress in epidermolysis bullosa research: Toward treatment and cure

Journal of Investigative Dermatology

Volumn 130, Issue 7, 2010, Pages 1778-1784

  Uitto, Jouni ^a   McGrath, John A ^b   Rodeck, Ulrich ^a   Bruckner Tuderman, Leena ^c   Robinson, E Clare ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d DEBRA International   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COLLAGEN TYPE 7; ETHYLPYRUVIC ACID; KALININ; NEUTRALIZING ANTIBODY; PYRUVIC ACID DERIVATIVE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1 ANTIBODY; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; BASEMENT MEMBRANE; BONE MARROW TRANSPLANTATION; CELL BASED GENE THERAPY; CLINICAL TRIAL; EPIDERMOLYSIS BULLOSA; EX VIVO GENE TRANSFER; GENE MUTATION; GENETIC HETEROGENEITY; GRANULATION TISSUE; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL RESEARCH; MOLECULAR THERAPY; MORBIDITY; MORTALITY; NONHUMAN; PATIENT ADVOCACY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; RNA SPLICING; SKIN FIBROSIS; SKIN INFLAMMATION; SPLICEOSOME; SQUAMOUS CELL CARCINOMA; VIRAL GENE THERAPY; WOUND HEALING IMPAIRMENT;

EID: 77953611510     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.90     Document Type: Review

References (39)

1. Arbiser JL, Fan CY, Su X et al. (2004) Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 123:788-790
2. Barrientos S, Stojadinovic O, Golinko MS et al. (2008) Growth factors and cytokines in wound healing. Wound Repair Regen 16:585-601
3. Chino T, Tamai K, Yamazaki T et al. (2008) Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 173:803-814
4. Chopra V, Tyring SK, Johnson L et al. (1992) Peripheral blood mononuclear cell subsets in patients with severe inherited forms of epidermolysis bullosa. Arch Dermatol 128:201-209
5. Christiano AM, McGrath JA, Hillman E et al. (2009) Reduced intensity conditioning and allogeneic stem cell transplantation in recessive dystrophic epidermolysis bullosa. J Invest Dermatol 129(Suppl 1):S56
6. Chung CH, Parker JS, Karaca G et al. (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5:489-500
7. Chung HJ, Uitto J (2010) Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa. Dermatol Clin 28:93-105
8. Dong G, Loukinova E, Chen Z et al. (2001) Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res 61:4797-4808
9. Fine JD, Eady RAJ, Bauer EA et al. (2008) The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 58:931-950
10. Fine JD, Mellerio JE (2009a) Extracutaneous manifestations and complications of inherited epidermolysis bullosa: Part I. Epithelial associated tissues. J Am Acad Dermatol 61:367-384
11. Fine JD, Mellerio JE (2009b) Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 61:387-402
12. Fine JD, Johnson LB, Weiner M et al. (2009) Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience. J Am Acad Dermatol 60:203-211
13. Fitch E, Harper E, Skorcheva I et al. (2007) Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9:461-467
14. Fritsch A, Kern JS, L S et al. (2009) Conditional collagen VII inactivation allows analysis of anchoring fibril stability and function in vivo and reveals a major role of fibroblasts in collagen VII expression. J Invest Dermatol 129(Suppl 1):S81
15. Gostynski A, Deviaene FC, Pasmooij A et al. (2009) Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br J Dermatol 161:444-447
16. Groves RW, Liu L, Dopping-Hepenstal PJ et al. (2010) A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol PMID: 20164846
17. Heinonen S, Männikkö M, Klement JF et al. (1999) Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J Cell Sci 112:3641-3648
18. Kivisaari AK, Kallajoki M, Mirtti T et al. (2008) Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas. Br J Dermatol 158:778-785
19. Langowski JL, Zhang X, Wu L et al. (2006) IL-23 promotes tumor incidence and growth. Nature 442:461-465
20. Mallipeddi R, Keane FM, McGrath JA et al. (2004a) Increased risk of squamous cell carcinoma in junctional epidermolysis bullosa. J Eur Acad Dermatol Venereol 18:521-526
21. Mallipeddi R, Wessagowit V, South AP et al. (2004b) Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa. J Invest Dermatol 122:1302-1309
22. Mavilio F, Pellegrini G, Ferrari S et al. (2006) Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 12:1397-1402
23. Mössner R, Schön MP, Reich K (2008) Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol 26:486-502
24. Neven B, Prieur AM, Quartier dit Maire P (2008) Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 4:481-489
25. Remington J, Wang X, Hou Y et al. (2009) Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa. Mol Ther 17:26-33
26. Sargent JL, Milano A, Bhattacharyya S et al. (2010) A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 130:694-705
27. Satwani P, Cooper N, Rao K et al. (2008) Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 50:1-8
28. Tamai K, Kaneda Y, Uitto J (2009) Molecular therapies for heritable blistering diseases. Trends Mol Med 15:285-292
29. Terry SF, Terry PF, Rauen KA et al. (2007) Advocacy groups as research organizations: the PXE International example. Nat Rev Genet 8:157-164
30. Tolar J, Ishida-Yamamoto A, Riddle M et al. (2009) Correction of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113:1167-1174
31. Tomita Y, Sato-Matsumura KC, Sawamura D et al. (2003) Simultaneous occurrence of three squamous cell carcinomas in a recessive dystrophic epidermolysis bullosa patient. Acta Dermatol Venereol 83:225-226
32. Tyring SK, Chopra V, Johnson L et al. (1989) Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. Arch Dermatol 125:797-800
33. Uitto J (2009) Progress in heritable skin diseases: translational implications of mutation analysis and prospects of molecular therapies. Acta Dermatol Venereol 89:228-235
34. Wagner JE, Ishida-Yamamoto A, McGrath JA et al. (2009) Adult stem cells for treatment of recessive dystrophic epidermolysis bullosa (RDEB). J Invest Dermatol 129(Suppl):S55
35. Wang L, Yi T, Kortylewski M et al. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206: 1457-1464
36. Wessagowit V, Mallipeddi R, McGrath JA et al. (2004) Altered expression of L-arginine metabolism pathway genes in chronic wounds in recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol 29:664-668
37. Wong T, Gammon L, Liu L et al. (2008) Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 128:2179-2189
38. Young VL, Bush J, O'Kane S (2009) A new approach for the prophylactic improvement of surgical scarring: avotermin (TGF beta 3). Clin Plastic Surg 36:307-313 viii
39. Zhu Y, Hu C, Lu M et al. (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162-175